ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Melanoma

The Role of Intralesional Therapies in Melanoma

Sanjiv S. Agarwala, MD
Through the emergence of new immunotherapies, treatment of melanoma is undergoing a long-awaited revolution. Ongoing research will clarify the outlines of the place that intralesional therapies will occupy in the therapeutic armamentarium in the years ahead.

Melanoma

A multicenter study showed that an occurrence of posttransplant skin cancer was common among a group of organ transplant recipients.

Participation in a training program increased levels of self-confidence for both patients and their partners in performing skin self-examinations to detect melanoma.

Effective systemic therapy for the treatment of stage III melanoma has emerged. Whether this influences treatment choice in stage III melanoma patients with in-transit metastases is the subject of this review.

In the recent era of effective systemic therapies for melanoma, the provocative question of whether isolated limb perfusion still plays a role in the treatment of patients with in-transit melanoma metastases is timely and relevant.

Reducing the use of indoor tanning by enforcing an age restriction could potentially reduce melanoma incidence, mortality, and the costs associated with treating the disease, according to results of an economic analysis.

Researchers have identified characteristics associated with improved outcomes when treating BRAF-mutated advanced melanoma with the combination of dabrafenib and trametinib.

An individual’s clinical risk factors could help guide skin cancer screening and identify those at high risk for melanoma who could benefit from increased surveillance.

Pages

Subscribe to Melanoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.